Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is a fundamentally strong company that is set for future growth due to its partnerships and new developments in its product line. With a strong brand reputation and projected earnings growth, HAE's stock has a Buy rating and potential for sustained success in the competitive medical technology industry. The company's financials and key data metrics support this positive outlook, with a strong revenue guidance and expected benefit from new products and acquisitions.

Bears say

Haemonetics is a medical technology company that operates in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. While the company has a strong presence in the growing plasma collection market and is experiencing growth in its core Plasma division, their Blood Center business is being rationalized to shed less profitable revenue. The company also faces stiff competition in the MedSurg segment and potential challenges in integrating its recent acquisitions, which may impact their overall financial performance in the future.

Haemonetics (HAE) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 8 analysts, Haemonetics (HAE) has a Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.